The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic analysis of clear cell carcinoma.
 
Nirav Haribhakti
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Phillip Walker
Employment - Caris Life Sciences
 
Eric I Marks
Honoraria - Brand Institute; M3; Medscape; Sermo
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics
Research Funding - D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Advanced Therapeutics; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; Meyer Consulting; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Daiichi Sankyo; Eisai; EOM Pharmaceuticals; Gaido; Iylon; Loxo; Merck; NeoMed; Pfizer; Prosperdtx; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley
 
Eugenia Girda
No Relationships to Disclose
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - AstraZeneca; Celsion; Eisai; GlaxoSmithKline; Immunogen; Iovance Biotherapeutics; Merck; Novocure; Seagen
Research Funding - GlaxoSmithKline (Inst); Merck (Inst)
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Don S. Dizon
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; i-Mab; Oasmia Pharmaceutical AB; Pfizer; Regeneron; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Kazia Therapeutics (Inst); Pfizer (Inst)